A role for AP-1 transcription factors like JunD in MLLr and NPM1 mutant acute leukemias has not been explored yet, but the first clinical trial results with menin–MLL inhibitors combined with our menin mutant results motivate future studies of these inhibitors on the menin–JunD interaction and its possible functional involvement in acute leukemias. The gene discussed is MEN1; the disease is acute leukemia.